DISCARDED

About HeartSciences

A Healthcare IT company enabling earlier cardiac triage and screening through AI-enabled ECG management, backed by 23+ peer-reviewed publications.

Our Mission

To enable accurate and affordable solutions for the early detection of heart disease.

Cardiovascular disease remains the leading cause of death globally, often because critical conditions go undetected until it's too late. Traditional ECG interpretation misses subtle signs that could enable earlier intervention.

HeartSciences was founded to change that. By combining advanced AI algorithms with clinical-grade ECG acquisition, we're enabling healthcare providers to detect cardiac abnormalities earlier than ever before.

Our technology is the result of years of research, rigorous clinical validation, and collaboration with leading healthcare institutions around the world.

Mission Image

Our Values

Patient First

Everything we do is guided by our commitment to improving patient outcomes.

Scientific Rigor

Our technology is built on a foundation of peer-reviewed clinical research.

Integrity

We maintain the highest standards of ethics in everything we do.

Innovation

We continuously push the boundaries of what AI can achieve in healthcare.

Leadership Team

Our team brings together expertise in AI, cardiology, medical devices, and healthcare innovation.

AS

Andrew Simpson

Chairman & CEO

25+ years medical device experience, led multiple healthcare technology companies.

MH

Mark Hilz

Chief Operating Officer

Operational excellence in scaling healthcare technology companies globally.

FKD

Fiona Kathleen Duffy

VP Clinical & Regulatory

Extensive experience in FDA regulatory affairs and clinical trials.

MVDP

Meeshanthini V. Dogan, PhD

VP Research

Leading AI/ML research in cardiac screening with published work.

Board of Directors

AS

Andrew Simpson

Chairman

RE

Robert Eno

Director

MH

Mark Hilz

Director

DW

David Wells

Director

YMM

Yuri Maricich, MD

Director

Scientific Advisors

Leading researchers and clinicians advancing cardiac AI.

PPSM

Partho P. Sengupta, MD

BGP

Ben Glicksberg, PhD

GNM

Girish Nadkarni, MD

JSM

Jordan Strom, MD

AVM

Akhil Vaid, MD

JLM

Joshua Lampert, MD

Company Milestones

2015

Company Founded

HeartSciences established with a mission to enable earlier cardiac detection.

2017

First Algorithm

Development of initial AI algorithm for diastolic dysfunction detection.

2019

Clinical Trials

Multi-center clinical validation studies initiated across 12 medical centers.

2021

FDA Clearance

Received 510(k) clearance for MyoVista Insights software.

2022

Commercial Launch

Full commercial availability in the United States.

2023

International Expansion

CE marking obtained, expansion into European markets.

2024

Algorithm Expansion

Enhanced clearance for 12+ cardiac condition detection algorithms.

Ready to Improve Cardiac Detection?

See how 12 validated algorithms can help your clinicians detect cardiac dysfunction earlier. Schedule a 30-minute demo with our clinical team.

30-minute demo
Clinical evidence review
Custom pricing